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Nicholas S. McCarty 
Diabetes: A History 
Edward Albert Sharpey-Schafer is frantically pacing within his office at the University of 
Edinburgh. His scuffling feet are kicking up dust, filling the room with a musty and stale air. Open books 
lie scattered about the room, their titles ranging from Resection of the Pancreas to Malattie delle glandule 
salivary e del pancreas. Perhaps the most fascinating book, 
however, lies open on Schafer’s desk. His pen, uncapped upon 
the book's pages, drips black ink and blots the words.  
The year is 1910, and the scrawled handwriting in his 
journal shows--for the first time--that the pancreas is producing a 
previously unidentified substance. Schafer has identified a 
protein called insulin. The scientific sketches in his book are 
poised to transform the medical community for centuries to 
come. He will be knighted in only three years' time by King 
George V.  
The discovery of the insulin protein would prove to be a crucial advancement in the treatment of 
diabetes mellitus, a condition often characterized by high levels of glucose in the blood stream and a slow 
deterioration of organ function – including vision, kidney function, and sense of touch at the extremities. 
Insulin’s function in the body, and its role in treating patients with diabetes, would be uncovered, a few 
years after Shafer identified the hormone, by two men and a pack of dogs.  
The year is 1922, and the dust from World War I has barely settled. In Toronto, Dr. Frederick 
Banting and his student, Dr. Charles Best, don white coats--at least cpats that used to be white. Years of 
laboratory research have stained the once pristine attire. Their pockets are overflowing with filled 
syringes. Dogs are running amok and food lies scattered about the ground. A persistent barking can be 
heard down the hall, much to the annoyance of scientific colleagues. Banting and Best have issues besides 
peeved academics on their minds, however. Just last week, they extracted insulin from the pancreas of the 
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dogs. Then, they removed the pancreas from a few of the canines and watched their blood sugar levels 
skyrocket. Today, they are going to test their hypothesis. 
Banting and Best inject insulin into five of the dogs 
without a pancreas. Then, with a careful eye on their pocket 
watches, they take blood from the dogs after fifteen, thirty, and 
sixty minutes. After performing careful tests on the collected 
blood, they determine that the animals’ blood sugar levels dropped 
after receiving injections of insulin. Banting and Best conclude 
that insulin can be used as a treatment for diabetic patients with 
hyperglycemia, or high concentrations of blood sugar. Based on 
these experiments, they determine that the pancreas secretes 
insulin, and thus must be the physiological regulator of blood 
glucose levels, as only the dogs with their pancreas removed had 
hyperglycemia. After further experiments and validation, Banting and Best’s paper is quickly written up 
and published in The Journal of Laboratory and Clinical Medicine. Banting goes on to win the Nobel 
Prize in Medicine only a year later, at the age of 32. He remains the youngest Nobel laureate in the area of 
Physiology or Medicine to this day. 
A few years after the publication of Banting and Best's groundbreaking manuscript, clinicians in 
academic hospitals around the world begin extracting insulin from healthy animals and humans and 
injecting it into people afflicted with hyperglycemia. In 1923, Eli Lilly and Company begin producing 
insulin on a commercial level. 
The year is 1949. Dr. Rachmiel Levine’s brow is furrowed, his feet incessantly tapping on the 
cement floor. The latest edition of Nature lies open on his desk. Inside is an article that states "insulin 
must enter the cell before sugar can pass through the cell membrane." The authors of the article argue that 
insulin is absorbed by cells, whereupon it activates the signaling pathway responsible for lowering blood 
glucose levels.  
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Model of the ‘Levine effect’, which demonstrates the manner in which 
insulin allows for glucose to enter the cell. The green squares are 
insulin molecules and the blue circles are glucose molecules. When 
insulin binds to the Insulin Receptor (orange), an activation signal 
notifies the glucose transporter (brown) to take in glucose. 
Levine, in his experiments at the Michael Reese 
Hospital in Chicago, has seen otherwise. Levine fed dogs sugar 
and then calculated the dilution level of the sugar, observing 
that it was concentrated only outside of cells. Once he injected 
insulin into the canines, however, the sugar entered the cells 
while the insulin remained outside, thus demonstrating that 
insulin “opens” the cell membrane to allow sugar entry. 
Contrary to the scientific belief held by many of his colleagues, 
insulin was not absorbed by the cell at all--it merely served as a ‘key’ to lower blood sugar levels. As a 
tribute to Levine’s findings, the standard explanation of the sugar transport mechanism in cells is called 
the "Levine effect." 
Further research in the fields of 
metabolism and endocrinology has 
demonstrated that insulin is a small 
protein that binds to cellular receptors, 
thus initiating a "signaling cascade" that 
brings glucose transporters to the 
membrane to begin taking in sugars. 
Figure 1 shows this process. The green 
squares represent insulin and the blue 
circles represent glucose. Insulin "sticks" 
to a receptor on the surface of cells 
(aptly named the Insulin Receptor) and 
triggers an activation signal that allows a 
protein known as the Glucose 
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Transporter to begin "absorbing" glucose from outside of the cell. This "sticking" of insulin and 
subsequent uptake of sugar is crucial to a healthy body because our cells use glucose to create energy. 
Unfortunately, diabetic patients either do not produce enough insulin or cannot adequately absorb glucose 
into their cells.  
This theory, put forth by Levine, places diabetes research on a trajectory of mechanistic work, 
allowing scientists to ask more detailed questions and solve them using rigorous observation and 
validation. Instead of merely noting different diabetes symptoms, researchers begin to explore how 
diabetes impacts cells at the level of specific proteins, receptors and signaling pathways – that is, how 
diabetes works at the molecular level. In this way, they develop highly targeted and effective treatments.  
The year is 1959. Dr. Solomon Berson and Dr. Rosalyn Yalow are hard at work in the Bronx 
Veteran Affairs Hospital. Yalow had earned a PhD in Physics in 1945 from the University of Illinois at 
Urbana-Champaign, where she was the only woman 
among the department’s 400 members. Now, Drs. 
Berson and Yalow are on the verge of creating a new 
tool to allow scientists to study insulin and glucose in 
living cells. Both scientists are founding members of 
the Radioisotope Service in the hospital, a state-of-
the-art center that uses radioactivity to study how 
compounds are manipulated in the human body. 
Berson and Yalow have worked tirelessly in the lab to develop the radioimmunoassay, a technique that 
measures the concentration of proteins, such as insulin, in the blood through the use of antibodies and 
radioactive compounds. The assay paves the way for in vivo (in living organisms) measurements of 
insulin levels, and provides clinicians with a powerful tool to diagnose diabetic patients. In 1978, Dr. 
Yalow will become the first female President of the Endocrine Society. 
Today, the Abel laboratory at the University of Iowa is combining scientific research from the 
last century to improve the way that diabetic patients are treated. We use mice with specific genetic 
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deletions to study the role of different genes and proteins in the development and treatment of diabetes. 
After deleting a certain gene, we track the health of the mice over time to study the role of that gene in the 
cell. Innovative new machines and experimental techniques have drastically accelerated the rate of 
scientific progress, allowing us to 
answer questions at the molecular 
level in just a few days. The Fraternal 
Order of Eagles Diabetes Research 
Center was dedicated in April 2011 
after a gift of $25 million from the 
Fraternal Order of Eagles. Today, the 
Center houses more than 90 scientific 
investigators in different disciplines 
working on questions related to 
diabetes, insulin signaling, metabolism and cardiovascular function.  
A recent study from the Diabetes Research Center showed that removal of the Insulin Receptor in 
cells leads to early-onset heart failure, demonstrating a clear link between insulin signaling and heart 
function. Insulin is, in effect, a "glue" that holds the heart together. According to a 2014 Statistics Report 
by the Centers for Disease Control and Prevention, over 30 million Americans have been diagnosed with 
diabetes. Furthermore, about two-thirds of all diabetes-related deaths come about as a result of heart 
attacks and strokes. 
The tale of diabetes throughout time has shown that a "happily ever after" ending is not yet 
possible, but scientists have much to learn from their predecessors. By looking at the past, researchers can 
continue moving forward. What will the next decade hold? 
The Abel Laboratory at the Fraternal Order of Eagles Diabetes 
Research Center, University of Iowa. Picture taken in May of 2015. 
